Viridian Therapeutics Stock Price on November 8, 2024
| VRDN Stock | USD 21.87 0.04 0.18% |
Below is the normalized historical share price chart for Viridian Therapeutics extending back to June 18, 2014. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Viridian Therapeutics stands at 21.87, as last reported on the 29th of November, with the highest price reaching 22.25 and the lowest price hitting 21.49 during the day.
If you're considering investing in Viridian Stock, it is important to understand the factors that can impact its price. Viridian Therapeutics appears to be not too volatile, given 3 months investment horizon. Viridian Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.15, which indicates the firm had a 0.15% return per unit of risk over the last 3 months. By inspecting Viridian Therapeutics' technical indicators, you can evaluate if the expected return of 0.79% is justified by implied risk. Please review Viridian Therapeutics' Coefficient Of Variation of 759.95, risk adjusted performance of 0.1094, and Semi Deviation of 3.44 to confirm if our risk estimates are consistent with your expectations.
At this time, Viridian Therapeutics' Stock Based Compensation is very stable compared to the past year. As of the 29th of November 2024, Stock Based Compensation To Revenue is likely to grow to 224.62, while Capital Stock is likely to drop about 122 M. . At this time, Viridian Therapeutics' Price To Sales Ratio is very stable compared to the past year. As of the 29th of November 2024, Price Book Value Ratio is likely to grow to 3.95, while Price Earnings Ratio is likely to drop (4.31). Viridian Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 18th of June 2014 | 200 Day MA 17.2482 | 50 Day MA 22.7506 | Beta 1.114 |
Viridian |
Sharpe Ratio = 0.1451
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | VRDN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.46 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.79 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Viridian Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viridian Therapeutics by adding it to a well-diversified portfolio.
Price Book 3.3404 | Enterprise Value Ebitda (3.18) | Price Sales 5.7 K | Shares Float 71 M | Wall Street Target Price 40.625 |
Viridian Therapeutics Main Headline on 8th of November 2024
Acquisition by Fairmount Funds Management Llc of 1600000 sha... by Fairmount Funds Management Llc
Filed transaction by Viridian Therapeutics Director, 10 Percent Owner . Grant, award or other acquisition pursuant to Rule 16b-3
Viridian Therapeutics Valuation on November 8, 2024
It is possible to determine the worth of Viridian Therapeutics on a given historical date. On November 8, 2024 Viridian was worth 24.78 at the beginning of the trading date compared to the closed value of 25.21. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Viridian Therapeutics stock. Still, in general, we apply an absolute valuation method to find Viridian Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Viridian Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Viridian Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 24.03 | 25.02 | 24.03 | 24.71 | 1,452,559 | |
11/08/2024 | 24.78 | 25.28 | 24.39 | 25.21 | 889,408 |
| 25.59 | 26.06 | 25.21 | 25.71 | 1,367,133 |
| Backtest Viridian Therapeutics | | | Viridian Therapeutics History | | | Viridian Therapeutics Valuation | Previous | Next |
Viridian Therapeutics Trading Date Momentum on November 8, 2024
| On November 11 2024 Viridian Therapeutics was traded for 25.71 at the closing time. The top price for the day was 26.06 and the lowest listed price was 25.21 . The trading volume for the day was 1.4 M. The trading history from November 11, 2024 was a factor to the next trading day price boost. The trading price change against the next closing price was 1.98% . The trading price change against the current closing price is 20.35% . |
Viridian Therapeutics Fundamentals Correlations and Trends
By evaluating Viridian Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Viridian Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Viridian financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Viridian Therapeutics Stock history
Viridian Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Viridian is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Viridian Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Viridian Therapeutics stock prices may prove useful in developing a viable investing in Viridian Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 44.8 M | 47 M | |
| Net Loss | -116.9 M | -111 M |
Viridian Therapeutics Quarterly Net Working Capital |
|
Viridian Therapeutics Stock Technical Analysis
Viridian Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Viridian Therapeutics Period Price Range
Low | November 29, 2024
| High |
0.00 | 0.00 |
Viridian Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Viridian Therapeutics November 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Viridian Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Viridian Therapeutics shares will generate the highest return on investment. By undertsting and applying Viridian Therapeutics stock market strength indicators, traders can identify Viridian Therapeutics entry and exit signals to maximize returns
Viridian Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Viridian Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Viridian Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Viridian to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.1094 | |||
| Jensen Alpha | 0.4797 | |||
| Total Risk Alpha | (0.11) | |||
| Sortino Ratio | 0.1514 | |||
| Treynor Ratio | 0.3733 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viridian Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 0.005 | Quarterly Revenue Growth 0.194 | Return On Assets (0.32) | Return On Equity (0.52) |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.